Electromed Names Jim Cunniff as President and Chief Executive Officer
05 Juin 2023 - 2:15PM
Business Wire
Healthcare Executive Brings More Than 30 Years
of Executive Experience and Commercial Success to Electromed
Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader
in innovative airway clearance technologies, today announced the
appointment of Jim Cunniff as its new President and Chief Executive
Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join
Electromed’s Board of Directors.
“We are pleased to announce the appointment of Jim Cunniff as
president and CEO,” said Lee Jones, Chair of the Board. “Jim is a
proven executive with deep experience driving growth and
profitability through excellence in products and services that
benefit patients and support care teams.
“As Kathleen Skarvan, our current CEO retires, I want to thank
her for exceptional leadership over 10 years at Electromed. The
company is in a strong position as a result, and we are pleased
that she has agreed to continue to serve as Chair of the
Board.”
Mr. Cunniff brings over 30 years of executive leadership in the
MedTech and broader healthcare industry with demonstrated success
in general management, sales and marketing, finance, manufacturing,
distribution, mergers, and acquisitions. Mr. Cunniff will be
joining Electromed from his role as President, Chief Executive
Officer, and Board Director of Provista, a Vizient company, where
he consistently grew revenue, executed two acquisitions, and shaped
the strategic plan for the company. Previously, Cunniff was the
President, Chief Executive Officer, and Board Director for Leiters,
the Senior Vice President of Americas for Kinetics Concepts, and
the President of Emerging Markets for Stryker Corporation.
“I am thrilled that Jim Cunniff will be my successor as
President and Chief Executive Officer of Electromed and look
forward to working with him as I transition to the Chair role,”
said Kathleen Skarvan, longtime Chief Executive Officer of
Electromed. “I am incredibly proud of what the Electromed team has
accomplished under my leadership over the past decade, and I am
confident that Jim is the ideal candidate to lead Electromed into
its next phase of growth.”
“I am delighted to be joining this dynamic company, and to
collaborate closely with Kathleen, the Board and the management
team during the transition,” said Jim Cunniff, incoming President
and Chief Executive Officer. “I look forward to continuing to
deliver against strategic initiatives, grow commercial adoption and
deliver strong shareholder results.”
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that
provide airway clearance therapy, including the SmartVest® Airway
Clearance System, to patients with compromised pulmonary function.
It is headquartered in New Prague, Minnesota, and was founded in
1992. Further information about Electromed can be found at
www.smartvest.com.
Cautionary Statements
Certain statements in this press release constitute
forward-looking statements as defined in the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as
“anticipate,” “assume,” “believe,” “continue,” “expect,” “may,”
“potential,” “should,” “will,” and similar expressions, including
the negative of these terms, but they are not the exclusive means
of identifying such statements. Forward-looking statements cannot
be guaranteed, and actual results may vary materially due to the
uncertainties and risks, known or unknown associated with such
statements. Examples of risks and uncertainties for Electromed
include, but are not limited to, component or raw material
shortages, changes to lead times or significant price increases,
changes to Medicare, Medicaid, or private insurance reimbursement
policies; the duration, extent and severity of the COVID-19
pandemic, including its effects on our business, supply chain,
operations and employees as well as its impact on our customers and
distribution channels and on economies and markets more generally;
the competitive nature of our market; changes to state and federal
health care laws; changes affecting the medical device industry;
our ability to develop new sales channels for our products such as
the homecare distributor channel; our need to maintain regulatory
compliance and to gain future regulatory approvals and clearances;
new drug or pharmaceutical discoveries; general economic and
business conditions; our ability to renew our line of credit or
obtain additional credit as necessary; our ability to protect and
expand our intellectual property portfolio; the risks associated
with expansion into international markets, as well as other factors
we may describe from time to time in Electromed’s reports filed
with the Securities and Exchange Commission (including Electromed’s
most recent Annual Report on Form 10-K, as amended from time to
time, and subsequent Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K). Investors should not consider any list of
such factors to be an exhaustive statement of all of the risks,
uncertainties or potentially inaccurate assumptions investors
should take into account when making investment decisions.
Shareholders and other readers should not place undue reliance on
“forward-looking statements,” as such statements speak only as of
the date of this press release. We undertake no obligation to
update them in light of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005029/en/
Brad Nagel, Chief Financial Officer (952) 758-9299
investorrelations@electromed.com
Mike Cavanaugh, Investor Relations ICR Westwicke (617) 877-9641
mike.cavanaugh@westwicke.com
Electromed (AMEX:ELMD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Electromed (AMEX:ELMD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024